Medvance Linkedin
Medvance Linkedin



Time to reimbursement for orphan drugs in EU5 in the last five years

The primary objective of this analysis was to compare the time to reimbursement (TTR) for ODs in five European countries: France, Germany, Italy, Spain and the United Kingdom (UK).

Comparison of Market Access Routes of Digital Health Applications in France, Germany and the UK

New digital health applications (DHA) reaching the health care market and some have already proven a clear benefit for patients through RCTs. But how is it with the market access: Different countries handle DHAs similar to other health care products, others have implemented a special pathway. The objective of this analysis is to examine DHA market access routes in Germany, France and the UK.

Market access landscape for advanced therapy medicinal products in the EU-5

The aim of this poster is to compare the market access for ATMPs approved by the EMA
since 2015 across the EU5 countries focusing on reimbursement trends.